Autotelic Bio Inc.
RNA Therapeutics New Drug Development Company
15 employees · est. 2015 · Korea South
SanegeneBio
Sanegene Bio is committed to advancing transformative RNAi therapies that address global unmet medical needs.
28 employees · est. 2021 · Woburn, United States
Autotelic Bio Inc. is the older company (2015 vs 2021).
Side-by-Side Comparison
| Metric | Autotelic Bio Inc. | SanegeneBio |
|---|---|---|
| Founded | ||
| Founded | 2015 older | 2021 |
| Headquarters | ||
| Headquarters | Korea South | Woburn, United States |
| Employees | ||
| Employees | 15 | 28 |
| Industry | ||
| Industry | Biotechnology, Pharmaceutical | Not tracked yet |
| Funding Stage | ||
| Funding Stage | Series B | Series B |
| Total Funding | ||
| Total Funding | $22.00B | $190.00M |
| Funding Rounds | ||
| Funding Rounds | 3 | 2 |
| Services | ||
| Services | Not tracked yet | Drug Discovery and Development, Therapeutic Pipeline Management, RNAi Medicines, Targeted Delivery Platform |
| Target Customers | ||
| Target Customers | Not tracked yet | Patients with Metabolic Disorders, Individuals with Autoimmune Diseases, Healthcare Providers treating Cardiovascular Diseases, Biotech and Pharmaceutical Partners |
| Taxonomy | ||
| Taxonomy | RNA Therapeutics, Drug Development, Pharmaceutical Company, Clinical Stage, Nucleic Acid Therapies, RNA Interference (RNAi), ASO Platform, Immuno-oncology, IPF, FDCs, Antisense Oligonucleotide, Therapeutic Targeting, Precision Medicine, Biopharmaceuticals, Clinical Trials | RNAi Therapies, Genetic Medicines, Obesity Treatment, Cardiometabolic Diseases, Autoimmune Diseases, Drug Discovery, LEAD Technology, Tissue-specific Gene Silencing, Subcutaneous Dosing, RNA Interference, Metabolic Diseases, Cardiovascular Diseases, Immunology |
| Website | ||
| Website | autotelic.co.kr | sanegenebio.com |
About Autotelic Bio Inc.
Autotelic Bio Inc., a **clinical stage pharmaceutical company** founded in **2015** in **South Korea**, is making strides in the field of RNA therapeutics. The company's proprietary RNA interference (RNAi) ASO platform, **ASODE & CATs (Conjugated ASO Targeting Solution)**, sets it apart by enabling...
About SanegeneBio
Sanegene Bio, a clinical-stage biotechnology company, is committed to advancing transformative RNAi therapies that address global unmet medical needs. Founded in 2021 by industry veterans with deep expertise in RNA interference, Sanegene Bio leverages its proprietary LEAD™ platform to enable tissue-...
We will tell you when either one moves
BounceWatch watches Autotelic Bio Inc. and SanegeneBio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Autotelic Bio Inc. and SanegeneBio — by email.
Frequently Asked Questions
Compare Autotelic Bio Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Autotelic Bio Inc. on 12 Sep 2024, and SanegeneBio on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
